Glazer Capital LLC’s MoonLake Immunotherapeutics MLTX Stock Holding History

Glazer Capital LLC’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-58,541	Closed	-$577K	–	837
2021 Q3	$577K	Buy	58,541 +692	+1%	+$6.91K	0.01%	525
2021 Q2	$599K	Buy	57,849 +56,748	+5,154%	+$576K	0.01%	572
2021 Q1	$11K	Buy	+1,101	New	+$12.1K	﹤0.01%	742

Other funds holding MLTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Glazer Capital LLC's MLTX Position: Q4 2021 in Review

Glazer Capital LLC sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2021, closing a stake of 58,541 shares — an estimated $577K sold.

Glazer Capital LLC first reported a position in MLTX in Q1 2021 and held it in 3 quarters. The position peaked at $599K in Q2 2021. 45 funds tracked by Wall St. Rank hold MLTX as of Q4 2021.

Glazer Capital LLC reported no remaining MoonLake Immunotherapeutics position as of Q4 2021 after selling out during the quarter.
Glazer Capital LLC sold 58,541 MoonLake Immunotherapeutics shares in Q4 2021, an estimated $577K.
Glazer Capital LLC first reported a position in MoonLake Immunotherapeutics in Q1 2021 and held it in 3 quarters.
Glazer Capital LLC's MoonLake Immunotherapeutics position peaked at $599K in Q2 2021.
45 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2021.

Based on Glazer Capital LLC's 13F filing for Q4 2021, filed 14 Feb 2022.